Rocha-Singh KJ, Duval S, Jaff MR, et al. - Researchers carried out an individual patient data (IPD) meta-analysis to assess mortality. For the primary analysis, cox proportional hazards one-stage meta-analysis models using intention-to-treat methods were applied. They conducted a secondary analysis of additionally recovered missing vital status data. They evaluated the effect of control crossover to paclitaxel-containing devices (PTXD), cause-specific mortality and drug dose-mortality. This study distinguished 2,185 individuals and 386 deaths from eight PTXD trials with 4-year median follow-up. This IPD meta-analysis, based on the most complete available data set of mortality events from PTXD randomized controlled trials, distinguished an absolute 4.6% increased mortality risk correlated with PTXD use.